Company Overview and News
TORONTO, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Buffalo Coal Corp. (TSXV: BUF; JSE: BUC) (“Buffalo” or “the Company”) announced today that in light of recent developments including the uncertainty surrounding the continuation of the mining services contract provided by STA Coal Mining Company Proprietary Limited (“STA”) at the Company’s Magdalena underground mine in South Africa, the Company has suspended the strategic review process previously announced on May 4, 2018.
TORONTO, June 26, 2018 (GLOBE NEWSWIRE) -- Buffalo Coal Corp. (TSXV:BUF) (JSE:BUC) (“Buffalo” or “the Company”) announced today that it had completed a shares for debt arrangement with one of its creditors, STA Coal Mining Company Proprietary Limited (“STA”).
TORONTO, May 04, 2018 (GLOBE NEWSWIRE) -- Buffalo Coal Corp. (TSXV:BUF) (JSE:BUC) (“Buffalo” or “the Company”) shareholders are referred to the announcement, dated 20 March 2018, which advised, inter alia, that Buffalo Coal Dundee Proprietary Limited (“Buffalo Coal Dundee”), the Company’s wholly-owned subsidiary, had entered into an amendment (the “Amendment”) to the term loan and revolving credit facility with Investec Bank Limited and that as a further condition to the Amendment, the Company had retained Northcott Capital Limited as its financial advisor to conduct a review of its strategic options.
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- African Gold Group Inc. (TSX-V:AGG) (“AGG” or the “Company”) is pleased to announce the corporate and project updates set out below.
AGGFF CNR FBMCF AAUKF AAL AGG NGLOY BUF
TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Buffalo Coal Corp. (TSXV:BUF) (JSE:BUC) (“Buffalo” or “the Company”) announced today that Buffalo Coal Dundee Proprietary Limited (“Buffalo Coal Dundee”), the Company’s wholly-owned subsidiary, has entered into an amendment (the “Amendment”) to the term loan and revolving credit facility with Investec Bank Limited (“Investec” or the “Lender”) dated November 17, 2011, as amended from time to time (the “Investec Facility”).
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSXV:BUF / Buffalo Coal Corp on message board site Silicon Investor.